📰 Centric Services News
Page 5 - Centric Services News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Centric Services. Real-time updates on events, politics, business and more.
March 16, 2022
BrainStorm is generating stem cells to test its ALS drug in a genetic subpopulation after missing the mark in a Phase III trial.
March 2, 2022
Even if enrollment hiatus is lifted, logistical issues such as sending samples to and from Russia another setback.
February 25, 2022
HiberCell has commenced a first-in-human Phase Ia/b clinical trial of HC-7366 to treat advanced solid tumour patients.
February 22, 2022
Apart from gastric cancer, we also review Regenxbio in mucopolysaccharidosis type I and four Phase I trial updates.
February 18, 2022
Resverlogix has expanded the Phase IIb clinical trial for analysing apabetalone (RVX-208) as a potential oral Covid-19 therapy to Brazil.
February 18, 2022
Methodology:The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalDataâs Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A sma...
February 15, 2022
The RDIF have reported interim safety data of Phase II trials analysing the combination of AstraZeneca’s Covid-19 vaccine and Sputnik Light.
January 20, 2022
IIT Roorkee has won a national award for its outstanding research on citizen-centric services.
January 20, 2022
Roorkee: Indian Institute of Technology Roorkee’s team of researchers led by Prof. Dharmendra Singh has won the National “Gold” Award for e-governance for Outstanding Research on Citizen-Centric Services by Academic/Research Institutions. The t
January 19, 2022
Sorrento Therapeutics has secured the Brazilian ANVISA authorisation to start a Phase IIa trial of COVI-MSC for treating long COVID.